cbdMD, Inc. (NYSEAMERICAN:YCBD – Get Free Report) was the recipient of a significant growth in short interest in February. As of February 13th, there was short interest totaling 1,041,977 shares, a growth of 43.7% from the January 29th total of 725,021 shares. Currently, 10.6% of the shares of the company are sold short. Based on an average daily trading volume, of 687,845 shares, the short-interest ratio is presently 1.5 days. Based on an average daily trading volume, of 687,845 shares, the short-interest ratio is presently 1.5 days. Currently, 10.6% of the shares of the company are sold short.
Insider Buying and Selling at cbdMD
In related news, major shareholder Clark R. Crosnoe sold 550,701 shares of the company’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $2.32, for a total transaction of $1,277,626.32. Following the completion of the transaction, the insider owned 17,875 shares in the company, valued at $41,470. This represents a 96.86% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 6.50% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On cbdMD
A hedge fund recently bought a new stake in cbdMD stock. Jane Street Group LLC bought a new stake in cbdMD, Inc. (NYSEAMERICAN:YCBD – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 51,141 shares of the company’s stock, valued at approximately $69,000. Jane Street Group LLC owned about 0.49% of cbdMD as of its most recent filing with the Securities & Exchange Commission. 7.18% of the stock is currently owned by institutional investors and hedge funds.
cbdMD Stock Performance
cbdMD Company Profile
cbdMD, Inc (NYSEAMERICAN: YCBD) is a Charlotte, North Carolina–based producer and distributor of hemp-derived cannabidiol (CBD) products. Since its founding in 2018, the company has focused on developing a diverse portfolio of wellness offerings designed for human and pet use. Its product range includes tinctures, capsules, gummies, topicals, and pet-specific formulations, each developed to comply with U.S. Food and Drug Administration (FDA) guidelines for hemp-derived substances.
The company operates a vertically integrated business model, sourcing U.S.-grown hemp and overseeing manufacturing processes in cGMP-certified facilities.
Featured Articles
- Five stocks we like better than cbdMD
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
Receive News & Ratings for cbdMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for cbdMD and related companies with MarketBeat.com's FREE daily email newsletter.
